IBS008738 |
| Catalog No.GC65951 |
IBS008738 is a potent TAZ activator. IBS008738 stabilizes TAZ, increases the unphosphorylated TAZ level, enhances the association of MyoD with the myogenin promoter, upregulates MyoD-dependent gene transcription, and competes with myostatin in C2C12 cells. IBS008738 enhances myogenesis in C2C12 cells and facilitates muscle repair in a muscle injury model.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 385425-03-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IBS008738 is a potent TAZ activator. IBS008738 stabilizes TAZ, increases the unphosphorylated TAZ level, enhances the association of MyoD with the myogenin promoter, upregulates MyoD-dependent gene transcription, and competes with myostatin in C2C12 cells. IBS008738 enhances myogenesis in C2C12 cells and facilitates muscle repair in a muscle injury model[1][2].
IBS008738 (0, 24, 48, 72 h) enhances TAZ expression, with a peak at 24 h[1].
IBS008738 (10 μM; 0, 24, 72 h) enhances mRNAs of myogenic markers but not of myofusion markers[1].
IBS008738 (10 μM; 24h) enhances mRNAs of IL-10 in C2C12 cells[2].
Western Blot Analysis[1]
| Cell Line: | C2C12 cells |
| Concentration: | |
| Incubation Time: | Treated for 0, 24, 48, 72 h under differentiation conditions after 24 h under growth conditions. |
| Result: | Enhanced TAZ expression, with a peak at 24 h. |
RT-PCR[1]
| Cell Line: | C2C12 cells |
| Concentration: | 10 μM |
| Incubation Time: | 0, 24, 72 h under differentiation |
| Result: | Enhanced mRNAs of myogenic markers but not of myofusion markers. |
IBS008738 (3 nmol) facilitates muscle repair in Cardiotoxin-injected muscles[1].
IBS008738 (30 μM, 100 μL) prevents Dexamethasone-induced muscle atrophy[1].
IBS008738 (100-μL volume of 30 μM; intramuscular injection; immediately and on day 2 after TBI) diminishes the expression of TNF α and IL-6 but increases that of IL-10 mRNAs in muscles of traumatic brain injury (TBI)[2].
| Animal Model: | Six-week-old female BALB/cByJ mice[1] |
| Dosage: | 3 nmol (0.3 μL of 10 mM IBS008738 was diluted in 100 μL of PBS) |
| Administration: | Injected into the tibialis anterior (TA) muscle of mice under anesthesia. |
| Result: | Facilitated muscle repair in Cardiotoxin-injected muscles. |
| Animal Model: | Six-week-old female BALB/cByJ mice[1] |
| Dosage: | 30 μM (100 μL) |
| Administration: | Injected into the tibialis anterior (TA) and gastrocnemius (GM) muscles on days 9, 11, and 13. |
| Result: | Prevented Dexamethasone-induced muscle atrophy. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *